

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Clover Biopharmaceuticals, Ltd.**

**三葉草生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2197)**

**VOLUNTARY ANNOUNCEMENT**  
**CLOVER'S COVID-19 VACCINE CANDIDATE RECEIVES EU GMP**  
**CERTIFICATE**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**” or “**Clover**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors on the latest clinical development status of the core product of the Group.

The Company is pleased to announce that Clover’s contract development and manufacturing organization (“**CDMO**”) has received a European Union Good Manufacturing Practice (“**EU GMP**”) certificate for the production of Clover’s lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum). The EU GMP certificate is in connection with Clover’s regulatory submission to the European Medicines Agency (“**EMA**”) and follows a successful inspection of the CDMO site by the Ireland Health Products Regulatory Authority and signifies that the production of SCB-2019 (CpG 1018/Alum) meets the European Union’s standards for quality and safety.

The Company is working towards completing regulatory submissions to National Medical Products Administration (國家藥品監督管理局) of China, the EMA, and the World Health Organization for SCB-2019 (CpG 1018/Alum) in the second half of 2022, while concurrently preparing for its commercialization in China and globally upon receiving regulatory approvals.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to ultimately commercialize SCB-2019 (CpG 1018/Alum) successfully.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Clover Biopharmaceuticals, Ltd.**  
**Dr. Peng LIANG**  
*Chairman of the Board*

Shanghai, PRC, September 20, 2022

*As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Mr. Dong LYU, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.*